Mimicking the effects of bariatric surgery in obese and/or diabetic patients and reducing enteroendocrine activity in insulin-sensitive patients experiencing post-surgical hypoglycemia are both promising areas for developing new and effective treatments in the metabolic field. This evidence concerns the gene INS and Hypoglycemia.